- Carried out 16.5 million USD capital investment in addition to the 7.8 million USD invested last year

- Business diversification through joint development of therapeutic antibody

Bionote announced on the 8th of February, that they have entered into a contract with therapeutic antibody development company, Centenaire Biosciences ("Centenaire"), through which Bionote invested 16.5 million USD as capital investment.

The total investment amount amounts to 24.3 million USD, including the 7.8 million USD invested last year along with SD Investment. The total share held increased from 9.09% to 27%.

Bionote plans to continue their ongoing partnership with Centenaire through this investment, especially in co-developing new therapeutic antibody pipelines.

Centenaire is a sister company of Meditox, founded in 2021. They have been developing treatments for cancer, autoimmune diseases, and nervous system diseases through their innovative antibody platform technology. CTN001, which has been shown to be greatly effective for HER2 low-expression cancer has especially great market potential as the HER2 accounts for over 50% of breast cancers.

The two companies are planning for the clinical trials of the CTN001 product, signing a contract with Samsung Biologics and developing the process for the manufacture of clinical samples.

Furthermore, the two companies are also cooperating in the development of new treatments for non-small cell lung cancer and acute myeloid leukemia as well as cancer immunotherapy amongst various next generation anti-cancer treatments, expanding their research further.